Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on January 4, 2024. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Capital Market. Note: The request metadata references "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused solely on a listing compliance event.
Material Changes
The material change reported is the resolution of a minimum bid price deficiency. Previously, on July 7, 2023, the company received a 180-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. On January 4, 2024, the company received confirmation from the Nasdaq Listing Qualifications Staff that it has regained compliance and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The unusual item is the successful conclusion of the compliance period without further delisting action.
Investor Verification Checklist
- Verify the current trading price of CYCC to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the company's continued good standing on The Nasdaq Capital Market.
- Review the company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the company's capital structure or operational milestones.